Josephine van Dongen

Chapter 3 74 References 1. Hahne S, Hooiveld M,Vennema H, van Ginkel A, de Melker H,Wallinga J, van Pelt W, Bruijning-Verhagen P. Exceptionally low rotavirus incidence in the Netherlands in 2013/14 in the absence of rotavirus vaccination. Euro Surveill . 2014;19(43). 2. Verberk JDM, Bruijning-Verhagen P, de Melker HE. Rotavirus in the Netherlands; background information for the Health Council. In: RIVM Repor t. Bilthoven: National Institute of Public Health and the Environment; 2017. p. 1–70. 3. National Institute for Public Health and the Environment. State of Infectious Diseases in the Netherlands, 2016. http://www.rivm.nl/dsresource?objectid=bce6439b-ce72-49d3- b7ed-e0c42348c8c5&type=pdf&disposition=inline. 4. Enserink R, Scholts R, Bruijning-Verhagen P, Duizer E,Vennema H, de Boer R, Kor tbeek T, Roelfsema J, Smit H, Kooistra-Smid M, et al. High detection rates of enteropathogens in asymptomatic children attending day care. PLoS One. 2014;9(2):e89496. 5. Rijksinstituut voor Volksgezondheid en Milieu. RIVMVirologischeWeekstaten, Open Rappor tages [http://www.rivm.nl/Onderwerpen/V/Virologische_weekstaten/Rapportages/ Open_rapportages_virologische_weekstaten/Virologische_uitslagen_per_week_sinds_2006_ grafieken]. 6. van Gaalen RD, van de Kassteele J, Hahne SJM, Bruijning-Verhagen P,Wallinga J. Determinants of rotavirus transmission: a lag nonlinear time series analysis. Epidemiology. 2017;28(4):503–13. 7. Braeckman T,Theeten H, Lernout T, Hens N, Roelants M, Hoppenbrouwers K,Van Damme P. Rotavirus vaccination coverage and adherence to recommended age among infants in Flanders (Belgium) in 2012. Euro Surveill . 2014;19(20:pii=20806) 8. Rieck T,Wichmann O, Siedler A. Aktuelles aus der KV-Impfsurveillance; Impfquoten der rotavirus-, Masern-, HPV- und Influenza-Impfung in Deutschland. Epidemiologisches Bulletin. 2017;2017(1) 9. Public Health England. National rotavirus immunisation programme update: preliminary vaccine coverage for England, February 2016 to July 2016. In: Infection Repor t. vol. 10 Number 32: Health Protection Report ; 2016. 10. de Hoog MLA,Vesikari T, Giaquinto C, Hupper tz HI, Mar tinon-Torres F, Bruijning- Verhagen P. Repor t of the 5th European expert meeting on rotavirus vaccination (EEROVAC). Hum Vaccin Immunother. 2018;14(4):1027–34. 11. Bruijning-Verhagen P, Mangen MJ, Felderhof M, Har twig NG, van Houten M,Winkel L, deWaal WJ, Bonten MJ.Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med . 2013;11:112. 12. deWit MA, Koopmans MP, Kor tbeek LM,Wannet WJ,Vinje J, van Leusden F, Bar telds AI, van DuynhovenYT. Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol . 2001;154(7):666–74. 13. deWit MA, Koopmans MP, Kor tbeek LM, van Leeuwen NJ, Bar telds AI, van DuynhovenYT. Gastroenteritis in sentinel general practices,The Netherlands. Emerg Infect Dis. 2001;7(1):82–91. 14. Bruijning-Verhagen P, Sankatsing V, Kunst A, van den Born C, Bleeker E,Thijsen S, Ijzerman EP, van der Velden VH, Bonten MJ. Rotavirus-related hospitalizations are responsible for high seasonal peaks in all-cause pediatric hospitalizations. Pediatr Infect Dis J . 2012;31(12):e244–9. 15. National Institute for Public Health and the Environment.The National Immunisation Programme in the Netherlands: developments in 2009 [http://www.rivm.nl/bibliotheek/ rappor ten/210021012.pdf].